Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Caution still advised despite ever-improving drugs

30.11.2012
World AIDS Day: Results of Swiss HIV Cohort Study

Combination therapies for AIDS are becoming increasingly effective, but they cannot protect against other sexually transmitted illnesses. It is unsafe for patients taking antiretroviral drugs to stop using condoms. This is one of the findings of research conducted in the Swiss HIV Cohort Study, which is supported by the SNSF.

Drugs for HIV, the virus causing AIDS, have existed for more than two decades. Therapies have been continually refined and the standard approach in the West is now a combination therapy involving various antiretroviral substances. The rationale behind this idea is that the constantly changing virus finds it harder to develop resistances against three or more drugs administered simultaneously.

Less resistance to new drugs
At the beginning of the year, Huldrych Günthard (University Hospital Zurich) and his colleagues from the Swiss HIV Cohort Study showed (*) that new combination therapies are better at keeping viruses in check than the therapies used ten years ago. For the older therapies, resistant viruses developed on average 2.6 times per 100 patient-years (i.e. 100 patients over the course of one year, 50 over the course of two years) while resistance to the newer therapies developed only 1.5–1.9 times. Researchers believe that this improvement is not only the result of greater drug effectiveness – patients also tend to take the drugs more regularly because they have less side-effects.
Dramatic spread of hepatitis C
The continual improvement of combination therapies reduces the risk of HIV transmission. Recently published results of the Swiss HIV Cohort Study (**) suggest that this leads to a false sense of security in certain patients. Figures show that hepatitis C has spread rapidly among HIV-positive gay men during the last few years. While the rate of infection among heterosexuals has remained low (on average 0.4 infections per 100 patient-years), it has risen drastically among homosexuals: 4.1 persons are infected per 100 patient-years. This rate is 18 times higher than the one recorded in 1998.

Researchers point to the inconsistent use of condoms as the greatest risk factor. While the fear of AIDS has understandably diminished, there may be a tendency now to neglect other sexually transmitted illnesses. "Caution is still called for," says Günthard.

(*) von Wyl V, Yerly S, Böni J, Shah C, Cellerai C, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Ledergerber B, Günthard HF; Swiss HIV Cohort Study (2012). Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin Infect Dis. 54:131-40

(**) Wandeler G, Gsponer T, Bregenzer A, Günthard HF, Clerc O, Calmy A, Stöckle M, Bernasconi E, Furrer H, Rauch A; Swiss HIV Cohort Study (2012). Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic. Clin Infect Dis. 55:1408-1416

(Available as a PDF from the SNSF; e-mail: com@snf.ch)

The Swiss HIV Cohort Study
Established in 1988, the Cohort Study aims to generate knowledge about HIV infection and AIDS as well as to improve the care given to patients. All Swiss hospitals specialising in HIV (Basel, Berne, Geneva, Lausanne, Lugano, St. Gallen and Zurich) have collected and analysed data from over 16,000 HIV-positive persons. Currently, more than 8,400 persons are taking part in the Swiss HIV Cohort Study. Almost a third of them are women.
Contact
Prof. Dr. med. Huldrych Günthard
Klinik für Infektionskrankheiten und Spitalhygiene
Universitätsspital Zürich
Rämistrasse 100
8091 Zürich
Tel.: +41 (0)44 255 34 50
E-mail: huldrych.guenthard@usz.ch

Abteilung Kommunikation | idw
Further information:
http://www.snsf.ch
http://www.shcs.ch/

Further reports about: Aids HIV HIV Cohort Study HIV-positive Hepatitis C SNSF

More articles from Health and Medicine:

nachricht Discovery points to a new path toward a universal flu vaccine
03.07.2015 | Rockefeller University

nachricht "CCS Telehealth Ostsachsen", Germany's largest telemedicine project, goes online in Dresden
02.07.2015 | Universitätsklinikum Carl Gustav Carus Dresden

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Viaducts with wind turbines, the new renewable energy source

Wind turbines could be installed under some of the biggest bridges on the road network to produce electricity. So it is confirmed by calculations carried out by a European researchers team, that have taken a viaduct in the Canary Islands as a reference. This concept could be applied in heavily built-up territories or natural areas with new constructions limitations.

The Juncal Viaduct, in Gran Canaria, has served as a reference for Spanish and British researchers to verify that the wind blowing between the pillars on this...

Im Focus: X-rays and electrons join forces to map catalytic reactions in real-time

New technique combines electron microscopy and synchrotron X-rays to track chemical reactions under real operating conditions

A new technique pioneered at the U.S. Department of Energy's Brookhaven National Laboratory reveals atomic-scale changes during catalytic reactions in real...

Im Focus: Iron: A biological element?

Think of an object made of iron: An I-beam, a car frame, a nail. Now imagine that half of the iron in that object owes its existence to bacteria living two and a half billion years ago.

Think of an object made of iron: An I-beam, a car frame, a nail. Now imagine that half of the iron in that object owes its existence to bacteria living two and...

Im Focus: Thousands of Droplets for Diagnostics

Researchers develop new method enabling DNA molecules to be counted in just 30 minutes

A team of scientists including PhD student Friedrich Schuler from the Laboratory of MEMS Applications at the Department of Microsystems Engineering (IMTEK) of...

Im Focus: Bionic eye clinical trial results show long-term safety, efficacy vision-restoring implant

Patients using Argus II experienced significant improvement in visual function and quality of life

The three-year clinical trial results of the retinal implant popularly known as the "bionic eye," have proven the long-term efficacy, safety and reliability of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

World Conference on Regenerative Medicine in Leipzig: Last chance to submit abstracts until 2 July

25.06.2015 | Event News

World Conference on Regenerative Medicine: Abstract Submission has been extended to 24 June

16.06.2015 | Event News

MUSE hosting Europe’s largest science communication conference

11.06.2015 | Event News

 
Latest News

Siemens receives order for offshore wind power plant in Great Britain

03.07.2015 | Press release

'Déjà vu all over again:' Research shows 'mulch fungus' causes turfgrass disease

03.07.2015 | Agricultural and Forestry Science

Discovery points to a new path toward a universal flu vaccine

03.07.2015 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>